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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor, mostly resistant to the standard treatments. NCL is
overexpressed in cancers and its inhibition impairs tumor growth. Herein we described, that NCL was overexpressed in human
specimens of PDAC, and low NCL staining patients had increased overall survival. Previously, we described a family of multivalent
pseudopeptides binding to NCL and inhibiting tumour growth. Here, NCL antagonist N6L, strongly impaired tumor growth, liver
metastasis formation and angiogenesis in an orthothopic mouse model of PDAC. N6L inhibited both human and mouse tumor cell
proliferation and invasion. Proteome analysis of endothelial cell secreted proteins showed that NCL inhibition decreased Ang-2 levels
and switched a pro-angiogenic signature. Importantly, Ang-2 levels were decreased in plasma of N6L-treated PDAC mice. The
analysis of tumor vasculature revealed a strong increase of pericyte coverage and vessel perfusion in parallel to an inhibition of tumor
hypoxia. As consequence of N6L-induced tumor vessel normalization, pre-treatment with N6L efficiently improved chemotherapeutic
drug delivery and increased the anti-tumor properties of gemcitabine in PDAC mice.
In conclusion, NCL inhibition is a new anti-tumor therapeutic strategy that dually blocks tumor progression and normalizes tumor
vessels improving the delivery and efficacy of chemotherapeutic drugs in PDAC cancers. Moreover, we identified Ang-2 as a potential
target and suitable response biomarker for N6L treatment in PDAC.
Citation Format: Maud-Emmanuelle Gilles, Federica Maione, Mélissande Cossutta, Gilles Carpentier, Laure Caruana, Silvia Di
Maria, Damien Destouches, Ksenya Shchors, Christopher Prochasson, Anne Couvelard, José Courty, Enrico Giraudo, Ilaria
Cascone. NCL targeting impairs the progression of pancreatic ductal adenocarcinoma and promotes tumor vessel normalization
through Ang-2 inhibition. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research;
2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3366.
©2016 American Association for Cancer Research.
 Back to top
Advertisement 
7/5/2021 Abstract 3366: NCL targeting impairs the progression of pancreatic ductal adenocarcinoma and promotes tumor vessel normalization through Ang-…
https://cancerres.aacrjournals.org/content/76/14_Supplement/3366 2/3
July 2016 
Volume 76, Issue 14 Supplement
Table of Contents


























 Related Articles 
  Cited By...
  More in this TOC Section
Advertisement 








Copyright © 2021 by the American Association for Cancer Research.
Cancer Research Online ISSN: 1538-7445 
Cancer Research Print ISSN: 0008-5472 
Journal of Cancer Research ISSN: 0099-7013 
American Journal of Cancer ISSN: 0099-7374
Advertisement 
